Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104433668> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2104433668 endingPage "1530" @default.
- W2104433668 startingPage "1526" @default.
- W2104433668 abstract "Once-weekly rifapentine 600 mg plus isoniazid (INH) during the continuation phase treatment of tuberculosis is associated with a relapse rate higher than that of twice-weekly rifampin plus INH. The safety and tolerability of higher rifapentine doses need to be determined. We conducted a prospective, randomized, double-blind trial of rifapentine at three doses (600, 900, and 1,200 mg) plus INH 15 mg/kg once weekly in the continuation phase treatment of culture-positive tuberculosis in 150 human immunodeficiency virus-seronegative adults. Outcome measures were discontinuation of therapy for any reason and adverse events on therapy. Treatment was discontinued in 3 of 52 (6%), 2 of 51 (4%), and 3 of 47 (6%) in the rifapentine 600-, 900-, and 1,200-mg treatment arms, respectively. Only one discontinuation, in the rifapentine 1,200-mg arm, was due to an adverse event possibly associated with study therapy. There was a trend toward more adverse events, possibly associated with study therapy, in the highest-dose arms (p = 0.051). Rifapentine 900-mg, once-weekly dosing appears to be safe and well tolerated and is being evaluated in Phase III efficacy trials of treatment of latent tuberculosis. Further evaluation of the safety and tolerability of rifapentine 1,200 mg is warranted." @default.
- W2104433668 created "2016-06-24" @default.
- W2104433668 creator A5002041230 @default.
- W2104433668 creator A5009649219 @default.
- W2104433668 creator A5034123739 @default.
- W2104433668 creator A5037082491 @default.
- W2104433668 creator A5037686480 @default.
- W2104433668 creator A5049678095 @default.
- W2104433668 creator A5068140387 @default.
- W2104433668 creator A5076748422 @default.
- W2104433668 creator A5078668477 @default.
- W2104433668 date "2002-06-01" @default.
- W2104433668 modified "2023-10-11" @default.
- W2104433668 title "A Prospective, Randomized, Double-Blind Study of the Tolerability of Rifapentine 600, 900, and 1,200 mg Plus Isoniazid in the Continuation Phase of Tuberculosis Treatment" @default.
- W2104433668 cites W1891583862 @default.
- W2104433668 cites W1963975384 @default.
- W2104433668 cites W2002358661 @default.
- W2104433668 cites W2042410585 @default.
- W2104433668 cites W2044550428 @default.
- W2104433668 cites W2059707463 @default.
- W2104433668 cites W2102212813 @default.
- W2104433668 cites W2140574477 @default.
- W2104433668 cites W2406071469 @default.
- W2104433668 doi "https://doi.org/10.1164/rccm.200201-047oc" @default.
- W2104433668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12045127" @default.
- W2104433668 hasPublicationYear "2002" @default.
- W2104433668 type Work @default.
- W2104433668 sameAs 2104433668 @default.
- W2104433668 citedByCount "66" @default.
- W2104433668 countsByYear W21044336682012 @default.
- W2104433668 countsByYear W21044336682013 @default.
- W2104433668 countsByYear W21044336682014 @default.
- W2104433668 countsByYear W21044336682015 @default.
- W2104433668 countsByYear W21044336682016 @default.
- W2104433668 countsByYear W21044336682017 @default.
- W2104433668 countsByYear W21044336682018 @default.
- W2104433668 countsByYear W21044336682019 @default.
- W2104433668 crossrefType "journal-article" @default.
- W2104433668 hasAuthorship W2104433668A5002041230 @default.
- W2104433668 hasAuthorship W2104433668A5009649219 @default.
- W2104433668 hasAuthorship W2104433668A5034123739 @default.
- W2104433668 hasAuthorship W2104433668A5037082491 @default.
- W2104433668 hasAuthorship W2104433668A5037686480 @default.
- W2104433668 hasAuthorship W2104433668A5049678095 @default.
- W2104433668 hasAuthorship W2104433668A5068140387 @default.
- W2104433668 hasAuthorship W2104433668A5076748422 @default.
- W2104433668 hasAuthorship W2104433668A5078668477 @default.
- W2104433668 hasConcept C126322002 @default.
- W2104433668 hasConcept C141071460 @default.
- W2104433668 hasConcept C142724271 @default.
- W2104433668 hasConcept C197934379 @default.
- W2104433668 hasConcept C2776967927 @default.
- W2104433668 hasConcept C2776991065 @default.
- W2104433668 hasConcept C2777288759 @default.
- W2104433668 hasConcept C2777975735 @default.
- W2104433668 hasConcept C2778375690 @default.
- W2104433668 hasConcept C2778715236 @default.
- W2104433668 hasConcept C2779806340 @default.
- W2104433668 hasConcept C2781069245 @default.
- W2104433668 hasConcept C71924100 @default.
- W2104433668 hasConcept C98274493 @default.
- W2104433668 hasConceptScore W2104433668C126322002 @default.
- W2104433668 hasConceptScore W2104433668C141071460 @default.
- W2104433668 hasConceptScore W2104433668C142724271 @default.
- W2104433668 hasConceptScore W2104433668C197934379 @default.
- W2104433668 hasConceptScore W2104433668C2776967927 @default.
- W2104433668 hasConceptScore W2104433668C2776991065 @default.
- W2104433668 hasConceptScore W2104433668C2777288759 @default.
- W2104433668 hasConceptScore W2104433668C2777975735 @default.
- W2104433668 hasConceptScore W2104433668C2778375690 @default.
- W2104433668 hasConceptScore W2104433668C2778715236 @default.
- W2104433668 hasConceptScore W2104433668C2779806340 @default.
- W2104433668 hasConceptScore W2104433668C2781069245 @default.
- W2104433668 hasConceptScore W2104433668C71924100 @default.
- W2104433668 hasConceptScore W2104433668C98274493 @default.
- W2104433668 hasIssue "11" @default.
- W2104433668 hasLocation W21044336681 @default.
- W2104433668 hasLocation W21044336682 @default.
- W2104433668 hasOpenAccess W2104433668 @default.
- W2104433668 hasPrimaryLocation W21044336681 @default.
- W2104433668 hasRelatedWork W2016392277 @default.
- W2104433668 hasRelatedWork W2019883403 @default.
- W2104433668 hasRelatedWork W2088371416 @default.
- W2104433668 hasRelatedWork W2134387693 @default.
- W2104433668 hasRelatedWork W2135242626 @default.
- W2104433668 hasRelatedWork W2314974897 @default.
- W2104433668 hasRelatedWork W2327481048 @default.
- W2104433668 hasRelatedWork W2588751641 @default.
- W2104433668 hasRelatedWork W2984188740 @default.
- W2104433668 hasRelatedWork W123209954 @default.
- W2104433668 hasVolume "165" @default.
- W2104433668 isParatext "false" @default.
- W2104433668 isRetracted "false" @default.
- W2104433668 magId "2104433668" @default.
- W2104433668 workType "article" @default.